

1. Polysaccharides from the South African medicinal plant

2. *Artemisia afra*: Structure and activity studies.

3. Paula Marie Braünlich^a, Kari Tvete Inngjerdigen^a, Marit Inngjerdigen^b, Quinton Johnson^c,

4. Berit Smestad Paulsen^a, Wilfred Thozamile Mabusela^{d*}.

5. ^a School of Pharmacy, University of Oslo, Norway

6. ^b Oslo University Hospital, Oslo, Norway

7. ^c Nelson Mandela Metropolitan University, George, South Africa

8. ^d Chemistry department, University of the Western Cape, Bellville, South Africa

9. Corresponding author. Tel.: +27 21 959 3052; Fax: +27 21 959 1281.

10. E-mail address: wmabusela@uwc.ac.za (W T Mabusela)

11. Abstract

12. *Artemisia afra* (Jacq. Ex. Willd), is an indigenous plant in South Africa and other parts of the

13. African continent, where it is used as traditional medicine mostly for respiratory

14. conditions. The objective of this study was to investigate the structural features of the

15. polysaccharides from the leaves of this plant, as well as the biological activities of the

16. polysaccharide fractions against the complement assay. Leaves of *Artemisia afra* were

17. extracted sequentially with organic solvents (dichloromethane and methanol), 50%

18. aqueous ethanol, and water at 50 and 100 °C respectively. The polysaccharide extracts

19. were fractionated by ion exchange chromatography and the resulting fractions were

20. tested for biological activity against the complement fixation assay. Active fractions were

21. further fractionated using gel filtration. Monosaccharide compositions and linkage

22. analyses were determined for the relevant fractions. Polysaccharides were shown to be of
23. the pectin type, and largely contain arabinogalactan, rhamnogalacturonan and
24. homogalacturonan structural features. The presence of arabinogalactan type II features as
25. suggested by methylation analysis was further confirmed by the ready precipitation of the
26. relevant polysaccharides with the Yariv reagent. An unusual feature of some of these
27. polysaccharides was the presence of relatively high levels of xylose as one of their
28. monosaccharide constituents. Purified polysaccharide fractions were shown to possess
29. higher biological activity than the selected standard in the complement assay. Digestion of
30. these polysaccharides with an endo-polygalacturonanase enzyme resulted in polymers
31. with lower molecular weights as expected, but still with biological activity which exceeded
32. that of the standard. Thus on the basis of these studies it may be suggested that
33. immunomodulating properties probably contribute significantly to the health-promoting
34. effects of this medicinal plant.

35. 1. Introduction

36. *Artemisia afra* is a plant which is used traditionally in South Africa against a variety of
37. indications. Some of these include internal worm infestation, cough, cold, fever, colic,
38. headache, loss of appetite, pain in the ear and malaria (Liu et al, 2009). The most common
39. way to use the plant is to inhale the steam after boiling the leaves in water, although it
40. may also be taken as a tea infusion (van Wyk et al. 2002). Other uses include putting the
41. leaves in the socks to prevent sweating; they are also used against hemorrhoids, diabetes,
42. digestive problems, on wounds and as insecticide (von Koenen, 2001). *Artemisia afra* is
43. one of the most used medicinal plants in South Africa, and other African countries as well;
44. the plant has been the object of various studies over the recent years, although focus has
45. mainly been on essential oils and low molecular weight compounds, mostly for their

46. association with antimicrobial and antioxidant activities. As one of those multi-purpose
47. medicinal plants, it has also been investigated for potential cardioprotective and
48. antidiabetic cytotoxic properties, for which results were shown to be positive in animal
49. experiments (Guantai and Addae-Mena, 1999; Issa and Bule, 2015; Sunmonu and
50. Afolayan, 2013). Cytotoxicity studies of an ethanol extract against HeLa cancer cells
51. followed by a bio-assay guided fractionation led to the isolation of a sesquiterpene
52. lactone, known as isalantolactone, as the main bioactive compound (Spies et al., 2013;
53. Venables et al, 2016). The plant has also been shown to contain products that indicate it to
54. have efficacy against experimental tuberculosis (Ntutela et al. 2009). Since water
55. extraction is one of the most common ways of preparation of products used from the
56. plant, it is interesting that little has been done on the compounds soluble only in water,
57. among these, the polysaccharides. Recent studies by various groups have shown that
58. polysaccharides may play an important role in illnesses related to the immune system.
59. (Paulsen and Barsett, 2005; Wangenstein et al, 2015; Yamada and Kiyohara, 2007). The
60. authors have also recently described the immunomodulating activity of pectic
61. polysaccharides from the South African medicinal plant *Lessertia frutescens*,
62. (syn. *Sutherlandia frutescens*), (Zhang et al. 2014). Thus it was of interest for us to study
63. the polysaccharides present in the above-ground parts of *Artemisia afra* and also
64. investigate possible effects in immunomodulating assays.

65. 2. Material and methods

66. 2.1 Plant material

67. The plant material, *Artemisia afra* Jacq. Ex Willd., Compositae, was collected from the
68. botanical gardens of the Montague Museum (Western Cape, South Africa) and consists of
69. the stalks and leaves of the plant; its identity was authenticated by Frans Weitz, a plant

70. systematist from the Department of Biodiversity and Conservation Biology, University of
71. the Western Cape, South Africa. (Voucher specimen number 6639 which is deposited in
72. the herbarium at the University of the Western Cape, Cape Town, South Africa.)

73. 2.2 Preparation of the polysaccharide fractions.

74. Prior to the extraction of the polysaccharides, the plant material was extracted with
75. organic solvents to remove lipophilic and low molecular weight substances. This was
76. performed in a Soxhlet apparatus, successively with dichloromethane and methanol. The
77. residue was then subjected to extraction with 50% ethanol in water, followed by
78. extraction with water at 50° C and finally water of 100° C. The 50% ethanol extract was
79. first evaporated to remove all ethanol present, and then filtered to remove material not
80. soluble in water. This extract was then treated in the same way as the two water extracts
81. described below. All fractions were subjected to ultrafiltration using a PALL suspended
82. screen channel Ultrasett with cut off 5 kD. The high molecular weight fractions were then
83. applied onto an anion exchange column, ANX Sepharose 4 Fast Flow, 5x20 cm, in chloride
84. form. The neutral polysaccharides were eluted with distilled water, and the acidic ones
85. with a NaCl- gradient, 0-1.5 M NaCl. The eluent flow was 2 ml/min. Fractions of 10 ml were
86. collected in a Pharmacia LKB SuperFrac fraction collector, and they were monitored for the
87. content of carbohydrate by the phenol-sulfuric acid method (Dubois et al., 1956). The
88. fractions were pooled, dialyzed using a cut-off of 3500D, against distilled water in order to
89. remove NaCl and then freeze-dried. All fractions were tested for bioactivity using the
90. complement assay described below. The fractions that proved to be bioactive were all
91. further fractionated by gel filtration using a Sephacryl S-200 matrix, Pharmacia Fine
92. Chemicals, 3x70cm. The eluent was 0.3 M sodium acetate; elution speed 1 ml/min and
93. fractions of 5 ml were collected and tested with the phenol-sulfuric acid method as

94. described above. Relevant fractions were pooled, dialysed against a cut off of 3500D,
95. freeze-dried and analysed for bioactivity using the complement assay. All fractions
96. obtained after gel filtration were objects for more detailed structural and bioactivity
97. studies.

98. **2.3. Determination of the monosaccharide composition**

99. The monosaccharide compositions of the all extracts and purified fractions were
100. determined by gas chromatography of the trimethylsilylated (TMS) derivatives of the
101. methyl-glycosides obtained after methanolysis with 3 M hydrochloric acid in anhydrous
102. methanol for 24 h at 80°C (Austarheim et al., 2012; Barsett et al. 1992; Chambers and
103. Clamp, 1971). Mannitol was used as an internal standard. The TMS derivatives were
104. analyzed by capillary gas chromatography on a Focus GC (Thermo Scientific, Milan,
105. Italy).

106. **2.4. Molecular weight determination**

107. The homogeneity and molecular weights of the purified polysaccharide fractions were
108. determined by size exclusion chromatography on a Superose 6 prepacked column
109. (Amersham Biosciences) combined with the Äkta system (FPLC, Pharmacia Äkta,
110. Amersham Pharmacia Biotech). Dextran polymers (Pharmacia) B512 (5.6 kDa), T8360
111. (19 kDa), T250 (233 kDa) and T500 (475 kDa) were used as calibration standards.
112. Approximately 5 mg of the samples were dissolved in 2 mL of 10 mM NaCl buffer, the
113. resulting solution was filtered through a Millipore filter (0.45 µm) and applied to the
114. column. The samples were eluted with 0.3 M sodium acetate at pH 5.2 at a flow rate of
115. 0.5 mL/min, collecting 2 mL fractions. The eluate was monitored with a Shimadzu RI
116. detector. The retention volume of the main peak of each sample was converted to

117. molecular weight based on a standard curve prepared on the basis of the standards
118. given above.

119. 2.5. Precipitation with the Yariv β -glucosyl reagent

120. Precipitation with the Yariv β -glucosyl reagent was performed on the samples as
121. described by van Holst and Clarke (1985). The Yariv β -glucosyl reagent forms a colored
122. precipitate with compounds containing certain types of AG-II structures. A solution of
123. Arabic gum in water (1 mg/mL) was used as a positive control.

124. 2.6. Determination of glycosidic linkages

125. Glycosidic linkage elucidation was performed by methylation studies. The fractions most
126. active in the complement assay from each extract were selected for linkage
127. determination. Prior to methylation, the uronic acids were reduced with NaBD₄ to their
128. corresponding neutral sugars. After reduction of the polymers, methylation, hydrolysis,
129. reduction and acetylation (Kim and Carpita, 1992) were carried out. The derivatives
130. were analyzed by GC-MS using a GCMS-QP2010 (Shimadzu) attached to a Restek Rxi-
131. 5MS capillary column (30 m; 0.25 mm i.d.; 0.25 μ m film). The injector temperature was
132. 280 °C, the ion source temperature 200 °C and the interface temperature 300 °C. The
133. column temperature was 80 °C when injected, then increased at 10 °C/min to 140 °C,
134. followed by 4 °C/min to 210 °C and then 20 °C/min to 300 °C. Helium was the carrier gas
135. (pressure control: 80 kPa.) The compounds represented by each peak were
136. characterized by their retention times and interpretation of their characteristic mass

137. spectra. The estimation of the relative amounts of each linkage type was related to the
138. total amount of each monosaccharide type as determined by methanolysis. Effective
139. carbon-response factors were applied for quantification (Sweet et al., 1975).

140. 2.7. Complement fixation assay

141. The complement fixation test is based on inhibition of hemolysis of antibody sensitized
142. sheep red blood cells (SRBC) by human sera as described by Michaelsen et al. (2000)
143. (Method A), using PMII, a polysaccharide from *Plantago major*, as the positive control.
144. Inhibition of lysis induced by the test samples was calculated by the formula $[(A_{\text{control}} -$
145. $A_{\text{test}})/A_{\text{control}}] \times 100\%$. From these data, a dose-response curve was created to calculate
146. the concentration of test sample giving 50% inhibition of lysis (ICH_{50}). A low ICH_{50} value
147. means a high complement fixation activity. The activity of all the polysaccharide
148. fractions are given as the ICH_{50} value of the positive control BP-II divided on the ICH_{50}
149. value of the sample.


150. 2.8. Degradation of the samples with endo polygalacturonase

151. 5 mg polysaccharide was dissolved in 3 mL 0.1 M NaOH for de-esterification. The
152. solution was left for 2 h and neutralized with acetic acid. 10 ml sodium acetate buffer,
153. pH 4.2 and 1 drop of toluene was added followed by 60 μ l endo-polygalacturonase M2
154. (Megazyme). The mixture was then kept at 37° C for 72 h. After boiling to denature the
155. enzyme, the mixture was filtered through a Millipore filter 0.45 μ m and the filtrate
156. concentrated to 1 ml prior to application on a PD-10 column. The PD-10 column was

157. then eluted as described by the manufacturer (Pharmacia), the high molecular weight
158. material freeze dried and subjected to monosaccharide determination and the
159. complement assay.

160. 3. Results and discussion

161. The dried plant material (406 g) was extracted as described. The fractionation scheme is
162. given in Fig 1 below: -



163. Figure 1: Fractionation scheme of *Artemisia afra*.
164. The yield obtained, of the fractions showing high activity in the complement assay, after
165. anion exchange chromatography and gel filtration is given in Table 1. The bioactive,
166. purified fractions were denominated as 50%EtOH, 50W, 100W1 and 100W2 and used

167. for further studies.

Original plant material, 406 g	Chromatography methods		
Fractions	Anion exchange	Gel chromatography	% of start material
50% EtOH	807 mg	207 mg	0.05%
50W	243 mg	60 mg	0.014%
100W1	1615 mg	355 mg	0.09%
100W2	1080 mg	712 mg	0.18%

168. Table 1. Yield based on dry plant material of the purified bioactive fractions obtained

169. after separation by anion exchange and gel chromatography

170. Structural analyses of the polysaccharides from *A. afra*

171. Monosaccharide analyses of the four fractions gave results typical for pectic

172. polysaccharides (Table 2).

Fraction	50%EtOH	50%EtOHE	50W	50WE	100W1	100W1E	100W2	100W2E
Monosaccharide								
Arabinose	19.0	15.9	12.6	12.2	10.6	9.5	3.5	4.7
Rhamnose	7.9	8.7	5.6	6.2	11.9	14.2	5.7	9.1
Fucose	0.4	0.2	0.4	0.4	0.6	0.6	0.6	1.2
Xylose	7.8	4.5	15.1	10.5	4.4	4.5	1.3	2.1
Mannose	3.2	3.1	3.1	2.2	4.7	1.3	7.5	2.8
Glucose	1.8	2.8	3.2	2.8	3.8	3.6	9.5	6.6
Glucuronic acid	4.4	4.3	8	5.7	5.7	4.2	4.5	2.2
Galactose	33.4	34.7	26.3	27.3	17.3	16.6	5.8	7.3
Galacturonic acid	22.1	22.9	25.7	30.4	41.0	4.8	61.6	63.2
4-O-Me-GlcA	tr.	2.9	tr.	2.3	tr.	0.7	tr.	0.8

172. Content of monosaccharides in the most bioactive fraction after separation by

173. anion-exchange chromatography and gel filtration, and the same after treatment with

174. endopolygalacturonase (E). All fractions, apart from 100W2 have high contents of

175. arabinose and galactose, indicating the presence of arabinogalactans, polymers

176. common in pectins as side chains to the main core. Galacturonic acid is present in fairly
177. high amounts, and with the content of rhamnose found, the polymers may contain a
178. main core consisting of a rhamnogalacturonan backbone linked with longer chains of
179. homogalaturonans. The other monosaccharides found are also often present in pectins
180. (Yamada and Kiyohara, 2007). The most striking of those is the relatively high amount of
181. xylose present, which may have an impact on the bioactivity, and this will be discussed
182. below. The molecular weights of these four fractions were 69, 88, 43 and 10 kD
183. respectively. After degradation of the polymers with the enzyme
184. endopolygalacturonase, the most bioactive fractions thus obtained also revealed the
185. presence of small amounts of 4-O-methylglucuronic acid, also frequently found in
186. pectins as terminal units (Yamada and Kiyohara, 2007).

187. The types of linkages in the four bioactive native fraction obtained were determined
188. based on the methylation experiments (Table 3).

Fraction	50%EtOH	50W	100W1	100W2	
Monosaccharide	Linkage type*	2. Ratio of the different linkage types [#]			
Arabinose	T <i>f</i>	10.1	4.6	5	1.4
	1,3 <i>f</i>	1.5	0.6	0.6	tr.
	1,5 <i>f</i>	5.9	4.3	2.8	1.3
	1,3,5 <i>f</i>	0.5	0.4	2.2	0.8
	1,2,5 <i>f</i>	1	2.7	n.d.	n.d.
Rhamnose	T <i>p</i>	2.3	3.4	1.9	3.5
	1,2 <i>p</i>	tr.	n.d.	5.4	1.2
	1,2,4 <i>p</i>	5.6	2.2	4.6	1
Xylose	T <i>p</i>	1.2	3.1	4.4	1.3
	1,4 <i>p</i>	6.6	12	n.d.	n.d.
Glucose	T <i>p</i>	tr.	tr.	1.1	1.9
	1,4 <i>p</i>	1.4	3.1	2.5	7.6
	1,4,6 <i>p</i>	0.4	0.1	0.2	n.d.
Glucuronic acid	T <i>p</i>	4.4	8	5.7	n.d.
Galactose	T <i>p</i>	7.1	7.7	6.4	tr.
	1,3 <i>p</i>	3	2.3	1.9	1.9
	1,6 <i>p</i>	10.4	8.4	5	n.d.
	1,3,6 <i>p</i>	11.7	7.1	3.5	2.5
	1,3,4,6 <i>p</i>	1.2	0.8	0.5	1.4
Galacturonic acid	T <i>p</i>	n.d.	tr.	n.d.	10.1
	1,4 <i>p</i>	20.2	24.5	37.3	51.5
	1,3,4 <i>p</i>	1.4	1.1	2.5	n.d.
	1,2,4 <i>p</i>	0.5	0.1	1.2	n.d.

190. Table 3. Linkage analyses of the bioactive polysaccharides. The linkage types for the

191. monosaccharides not mentioned were not detected. The linkages for fucose and

192. mannose are not included.

193. *T = non-reducing terminal unit; *f* = furanose; *p* = pyranose

194. #tr = trace; n.d. = not determined

195. The fractions were all rich in 1,4-linked galacturonic acid residues, and all except Fr.

196. 100W2 contained significant amounts of galacturonic acid residues, which additionally
197. were branched in either position 2 or 3. These are features which have recently been
198. shown to be present in polysaccharides from other medicinal plants, e.g. *Combretum*
199. *glutinosum*, where it is believed that xylose units are appended to these branch
200. positions (Glaeserud et al. 2011). It is thus interesting to note that terminal and 1,4-
201. linked xylose units are also found in the polysaccharides from *A. afra*. Rhamnose, often
202. part of the main RG I core as 1,2-linked units, is mainly found in Fr. 100W1 and 100W2,
203. while in all fractions rhamnose units linked both in positions 2 and 4 are present,
204. indicating that the 1,2-linkages are present in the RGI region while concomitantly
205. carrying branches at position 4. These features are also common in RGI units from other
206. plant polysaccharides (Yamada and Kiyohara, 2007).


207. Galactose normally constitutes the main core in the arabinogalactans I and II. Except in
208. FR. 100W2, the galactose units were mostly 1,6-linked, with substantial branching at
209. position 3, thus providing the important side chains often observed in AGII structures
210. (Van Holst and Clarke, 1985). The arabinose units, in their furanose form, are largely
211. present as non-reducing terminal and 1,5-linked units in the peripheral parts of these
212. side chains.

213. The Yariv reagent has the ability to precipitate polysaccharides containing
214. arabinogalactan type II. Depending on the length of the galactose chain, a precipitate
215. will form if galactose units contain branches at positions 3 and 6 (Kitazawa et al. 2013;
216. Paulsen et al, 2014, Van Holst and Clarke, 1985).

217. Since linkage analyses revealed the presence of galactose units which are linked at

218. positions 3 and 6, the four polysaccharide fractions were tested against the Yariv
 219. reagent. Fractions 50% EtOH, 50W and 100W1 precipitated with Yariv reagent, while
 220. fraction 100W2 did not, although 1,3,6-linkages were present. The specification of the
 221. Yariv reagent for binding to the AGPII containing the 1,3,6-linked galactoses, remained
 222. unknown for a long time. However recently, following a systematic investigation by
 223. Kitazawa et al. (2013), they concluded that the β -1,3 galactan chain should be at least 5
 224. units long in order to bind with the Yariv reagent, and the presence of 7 units was
 225. needed to form cross linkages and thus produce a precipitate. They also concluded that
 226. 1,6-linked chains did not bind the Yariv reagent. The results of our studies related to the
 227. Yariv test are displayed in Fig 2.

228. Based on the above theory, it was concluded that samples 50% EtOH, 50W and 100W1
 229. all contain sequences consisting of at least 7 units of β -1,3-linked galactose units in their
 230. arabinogalactan chains, while fraction 100W2, although containing 1,3-linked and 1,3,6-
 231. linked galactose units, probably had shorter chains of the β -1,3 galactose units, and
 232. hence was unable to form a precipitate.




233. Polysaccharides from other *Artemisia* species have also been studied. Yamada et al.
234. I (1985, 1986, and 1987) showed that the polysaccharides from the leaves of the
235. Japanese medicinal plant, *Artemisia princeps*, contain immunomodulatory
236. polysaccharides of the pectic type. The polysaccharides were shown to have a typical
237. rhamnogalacturonan type I backbone, in which position 4 of the 1,2 linked rhamnose
238. units were substituted with arabinogalactan type II sidechains, i.e. have galactose being
239. 1,3-; 1,6- and 1,3,6-linked, with arabinofuranose units attached at the peripheral parts
240. of these side chains. Furthermore, the polysaccharides contained 1,4-linked xylose units
241. which were attached to galacturonic acid, in addition to 1,4-linked galactose and
242. terminal glucuronic acid units. Pectic type polysaccharides have been found in other
243. *Artemisia* spp. *Artemisia absinthium* was recently studied (Correa-Ferreira et al., 2014),
244. and the basic structure was determined to be of the arabinogalactan type II. The
245. arabinose units were present as terminal, 1,2-, 1,5- and 1,3,5-linked units, which is
246. common in arabinogalactan type II polymers (Togola et al., 2008). Methylation analysis
247. of the polymer also provided evidence for the presence of 1,4-linked galacturonic acid
248. residues, and 1,2,4- and 1,3-linked rhamnose units. On the basis of the foregoing
249. discussion, it may be deduced that *Artemisia afra* contains polysaccharides with similar
250. basic structural features as other *Artemisia* species reported to date.

251. Biological activities of the polysaccharides from *A. afra*.

252. One of the main methods for in vitro determination of the effect of chemical
253. compounds on the immune system is the complement assay (Michaelsen et al., 2000).
254. The method used in our laboratory is not influenced by possible contamination with
255. lipopolysaccharides. Thus, the effects observed are an indication of an
256. immunomodulating effect, which may be either stimulating or depressing. Following

257. extraction of the plant material, the effect on the complement assay was the measure
 258. by which fractions were selected for further studies. It was found that the biological
 259. activities of the selected fractions were higher than those of the standard used (Fig.3),
 260. and after purification using gel filtration the activity was still relatively high compared to
 261. both the standard and other polysaccharides previously studied in our laboratory thus
 262. far.




263. Figure 3. Complement effect of the fractions, ICH50 values, related to ICH50 value of the
 264. standard polysaccharide, PMII. The values are presented as ICH50 PMII / ICH50 sample.
 265. The red bars are the results after anion exchange chromatography and the blue after
 266. purification by gel filtration. (for colour reproduction, both on web and in print)

267. Fig 3 shows that the fraction 50W and 100W1, after gel filtration were slightly more
 268. active than 50%EtOH, and 100W2, and were still more active than the standard used. It
 269. is also interesting to note that the EtOH and 50W fractions both lost activity after gel
 270. filtration. This shows that it is not only the highest molecular weight compounds that
 271. are active, lower molecular weight (but still higher than 3,5kD) water soluble
 272. compounds are also of interest to investigate, but these were not the object of the

273. present study.

274. The higher molecular weight fractions, being the most active, were also subjected to
275. enzymatic degradation with polygalacturonase, in order to find which part of the
276. molecule were the most responsible for the bioactivity shown for the purified polymers.
277. After the enzyme treatments, the samples were separated by gel filtration and the
278. different fractions tested for effects in the complement assay. Again the effect was
279. compared with the standard PMII and the results are displayed in Figure 4:



280. Figure 4. Complement effect of the fractions, ICH50 values, related to ICH50 value of the
281. standard polysaccharide, PMII. The values are presented as $\text{ICH50 PMII} / \text{ICH50 sample}$.
282. The blue bars are the results of the samples after gel filtration, and the green those with
283. highest activity after separation of the polygalacturonase degraded samples. (for colour
reproduction, both on web and in print)

284. The activity of fractions from samples 50% EtOH, 50W and 100W1 are still higher

285. compared to the standard, while the 100W2 is very low in activity (Fig. 4). The
286. monosaccharide composition of the fractions obtained after enzyme degradation is
287. given in Table. 1. There is relatively little change in the ratio between the
288. monosaccharide compositions of the parent polymers compared with the most active
289. fraction after enzyme degradation, but they are lower in molecular weight compared to
290. the native polymers. The most striking difference is that 4-O-methylglucuronic acid is
291. present in all fractions. When comparing the components of the four fractions, it is
292. evident that the fraction 100W2 has a very different overall structure than the other
293. three polymers. This is basically a polygalacturonan and has no branches on the
294. galacturonic acid residues. This sample has also a much lower molecular weight than the
295. other three fractions. Mw may have an influence on the biological activity as obtained in
296. the complement assay. It is also of interest that the three other polysaccharides all
297. contain xylose, and also have branch points on galacturonic acid. It was shown in the
298. polysaccharides from the Malian medicinal tree, *Combretum glutinosum* that the
299. presence of xylose on the galacturonic acid chain leads to higher effect in the
300. complement assay than polysaccharides devoid of many of those substituted
301. galacturonic acid units (Glaeserud et al, 2011). The polysaccharides found with high
302. bioactivity from *Lessertia frutescens* did also have the feature of xylose units linked to
303. the galacturonic acid chain (Zhang et al. 2014). The three most active fractions all have a
304. relatively large arabinogalactan type II part of the structure, and this is very small in
305. fraction 100W2. This is evident both from the data in Table 2, linkage analyses, and
306. Figure 3, the Yariv test, where this fraction gave no precipitation. Several other studies
307. have shown that the AGII structure is important for the effect in the complement assay,
308. and the structural requirements have been discussed above (Wangenstein et al, 2015).

309. It should also be noted that the polysaccharides present in the leaves of *Artemisia*
310. *princeps* also have strong effects in the complement system (Yamada et al. 1985, 1986)
311. These studies on the polysaccharides from *Artemisia afra* clearly show that the water-
312. soluble fraction of this plant contains biologically active polysaccharides, and that these
313. have an effect that may be of importance in immune modulation.

314. 4 Conclusion

315. *Artemisia afra* is a plant with several traditional uses as a medicinal plant in South
316. Africa, and some of these uses may influence the immune system. As the healers mainly
317. use water extracts, the polysaccharides present in the water extract of the aboveground
318. plant part were studied. The studies revealed the presence of pectin like
319. polysaccharides with side chains consisting of arabinogalactan type II structures. Three
320. of the polymers, 50%EtOH, 50W and 100W1 all contained substitution with xylose on
321. parts of the polygalacturonan chain, which is probably important for the bioactivity. The
322. polysaccharides were all tested in the complement assay for immunomodulating
323. properties, and 4 fractions were obtained giving significant effect in the *in vitro*
324. complement assay, thus indicating that the use of this plant as a remedy in traditional
325. African medicine may be substantiated.

326. 5 Acknowledgements.

327. We are indebted to the South African National Research Foundation for funding the
328. research carried out in these studies.

329. References:

330. Austarheim, I., Christensen, B. E., Hegna, I. K., Petersen, B. O.; Duus, J. O. Bye, R.,
331. Michaelsen, T.E., Diallo, D., Inngjerdingen, M.; Paulsen, B.S. 2012, Chemical and
332. biological characterization of pectin-like polysaccharides from the bark of the Malian
333. medicinal tree *Cola cordifolia*. *Carbohydrate Polymers* 89(1), 259-268.
334. Barsett, H., Paulsen, B. S., & Habte, Y. (1992). Further characterization of polysaccharides
335. in seeds from *Ulmus glabra* Huds. *Carbohydrate Polymers*, 18(2), 125-130.
336. Brendler, T., Eloff, J.N., Gurib-Fakim, A,m Phillips, L.D. eds. 2010. African Herbal
337. Pharmacopoeia, Graphic Press Ltd. Mauritius.
338. Chambers, R.E., Clamp, J.R. 1971. An assessment of methanolysis and other actors used
339. in the analysis of carbohydrate containing materials. *Biochemical Journal*. 125, 1009 –
340. 1018.
341. Correa-Ferreira, M.L., Noletto, G.R., Pekowicz, C.L.O. 2014, *Artemisia absinthium* and
342. *Artemisia vulgaris*: A comparative study of infusion polysaccharides. *Carbohydrate*
343. *Polymers*, 102, 738-745.
344. Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A., Smith, F. 1956, Colorimetric method
345. for determination of Sugars and related substances. *Analytical Chemistry*, 28, 350-356.
346. Glaeserud, S., Groenhaug, T.E., Michaelsen, T.E., Inngjerdingen, M., Barsett, H., Diallo,
347. D., Paulsen, B.S. 2011, Immunomodulating polysaccharides from leaves of the Malian

348. medicinal tree *Combretum glutinosum*; structural differences between small and large
349. leaves can substantiate the preference for small leaves by some healers . Journal of
350. Medicinal Plants Research, 5(13), 2781-2790.
351. Guantai, A. N.; Addae-Mensah, I., 1999. Cardiovascular effect of *Artemisia afra* and its
352. constituents. *Pharmaceutical Biology*, 37(5), 351-356.
353. Inngjerdigen, K. T.; Langerud, B. K.; Rasmussen, H.; Olsen, T. K.; Austarheim, I.;
354. Gronhaug, T. E.; Aaberge, I. S.; Diallo, D.; Paulsen, B. S.; Michaelsen, T. E. 2013, Pectic
355. Polysaccharides Isolated from Malian Medicinal Plants Protect against *Streptococcus*
356. *pneumoniae* in a Mouse Pneumococcal Infection Model. *Scandinavian Journal of*
357. *Immunology* 77,(5), 372-388.
358. Inngjerdigen, Kari Tvette; Thole, Christian; Diallo, Drissa; Paulsen, Berit Smestad;
359. Hensel, Andreas. 2014, Inhibition of *Helicobacter pylori* adhesion to human gastric
360. adenocarcinoma epithelial cells by aqueous extracts and pectic polysaccharides from
361. the roots of *Cochlospermum tinctorium* A. Rich. and *Vernonia kotschyana* Sch. Bip. Ex
362. Walp . *Fitoterapia*, 95, 127-132.
363. Issa I. A.; Bule H. M., 2015. Hypoglycemic Effect of Aqueous and Methanolic Extract of
364. *Artemisia afra* on Alloxan Induced Diabetic Swiss Albino Mice. Evidence-based
365. complementary and alternative medicine, 2015752486

366. Iwu, M.M. 2014. Handbook of African Medicinal Plants. CRC Press, Replika Press Pvt.
367. Ltd., India
368. Kim, J.B., Carpita, N.C. 1992. Changes in esterification of uronic acid groups of cell wall
369. polysaccharides during elongation of Maize coleoptiles. *Plant Physiology*, 98, 646-653.
370. Kitazawa, K, Tryfona, T., Yoshimi, Y., Hayashi, Y., Kawauchi, S., ANtonov, L., Tanaka, H.,
371. Takahashi, T., Kaneko, S., Dupree, P., Tsumuraya, Y. 2013. B-GALactosyl Yariv Reagent
372. Binds to the β -1,3 Galactan of Arabinogalactan Proteins. *Plant Physiology* , 161, 1117-
373. 1126.
374. Liu, N.Q., Van der Kooy, F., Verpoorte, R., 2009. *Artemisia afra*: A potential flagship for
375. African medicinal plants? *South African Journal of Botany* 75, 185–195.
376. Michaelsen. T.E., Gilje, A., Samuelsen, A.B., Høgåsen, K., Paulsen, B.S. 2000. Interaction
377. between human complement and a pectin type polysaccharide fraction, PMII, from the
378. leaves of *Plantago major* L. *Scandinavian journal of Immunology* 52, 483-490.
379. Mukinda, J.T., Eagles, P.F.K. 2010. The South African Pharmacopoeia Monograph project.
380. South African Medical Research Council, South Africa.
381. Ntutela, S., Smith, P., Matika, L., Mukinda, J., Arendse, H., Allie, N., Estes, D.M.,
382. Mabusela, W., Folb, P., Steyn L., Johnson, Q., Folk, W.R., Syce, J., Jacobs, M. 2009
383. Efficacy of *Artemisia afra* phytotherapy in experimental tuberculosis. *Tuberculosis* 89, S
384. 1, S33-40.

385. Paulsen, B.S., Barsett, H. 2005. Bioactive Pectic Polysaccharides, Adv. Polym. Sci 186; 69-
386. 101.
387. Paulsen B.S., Craik, D.J., Dunstan, D.E., Stone, B.A., Bacic, A. 2014, The Yariv reagent:
388. Behaviour in different solvents and interaction with a gum Arabic
389. arabinogalactanprotein. Carbohydrate Polymers 106, 460–468.
390. Spies, L., Koekemoer, T.C., Sowemimo, A.A., Goosen, E.D., van de Venter, M., 2013.
391. Caspase-dependent apoptosis is induced by *Artemisia afra* Jacq. ex Willd in a
392. mitochondria-dependent manner after G2/M arrest. South African Journal of Botany,
393. 84, 104–109.
394. Sunmonu T. O; Afolayan A. J., 2013. Evaluation of Antidiabetic Activity and Associated
395. Toxicity of *Artemisia afra* Aqueous Extract in Wistar Rats. Evidence-based
396. complementary and alternative medicine, 2013929074.
397. Sweet, D.P., Shapiro, R.H., Albersheim, P. 1975, Quantitative analysis by various GLC
398. [gas-liquid chromatography] response-factor theories for partially methylated and
399. partially ethylated alditol acetates . Carbohydrate Research, 40(2), 217-25.
400. Togola, A., Inngjerdigen, M., Diallo, D., Barsett, H., Rolstad, B., Michaelsen, T.E.,
401. Paulsen, B.S. 2008. Polysaccharides with complement fixing and macrophage

402. stimulation activity from *Opilia celtidifolia*, isolation and partial characterisation. Journal
403. of Ethnopharmacology, 115, 423-431.
404. Van Holst, G.-J., Clarke, E.E. 1985, Quantification of Arabino-galactan-protein in plant
405. extracts by single radial gel-diffusion. Analytical Biochemistry, 148, 446-450.
406. Van Wyk, B.-E., van Oudtshoorn, B., Gericke, N. 2002. Medicinal Plants of South Africa,
407. 2nd ed. Briza Publications, Pretoria, South Africa.
408. Venables, L.; Koekemoer, T. C.; Van de Venter, M.; Goosen, E. D., 2016.
409. Isoalantolactone, a sesquiterpene lactone from *Artemisia afra* Jacq. ex Willd and its in
410. vitro mechanism of induced cell death in HeLa cells. South African Journal of Botany,
411. 103, 216-221.
412. Von Koenen, E. 2001, Medicinal, Poisonous and Edible plants in Namibia, Klaus Hess
413. Publishers, 2001, Windhoek – Göttingen
414. Wangenstein, H., Diallo, D., Paulsen, B.S. 2015. Medicinal plants from Mali: Chemistry
415. and biology. Journal of Ethnopharmacology, 176, 429-437.
416. Yamada, H., Ohtani, K., Kiyohara, H., Cyong, J.C., Otsuka, Y., Yoshio, O. 1985. Purification
417. and chemical properties of Anti-complementary polysaccharides from the leaves of
418. *Artemisia princeps*. Planta Medica. 2, 121-125.

419. Yamada, H., Otsuka, Y., Omura, S. 1986. Structural studies on anti-complementary
420. polysaccharides from the leaves of *Artemisia princeps*. 4, 311-314.
421. Yamada, H., Kiyohara, H., Otsuka Y. 1987. Further structural studies of an anti-
422. complementary acidic heteroglycan from the leaves of *Artemisia princeps*. Carbohydrate
423. Research 170, 181-191.
424. Yamada, H., Kiyohara, H. 2007, "Comprehensive Glycoscience: from Chemistry to
425. Systems Biology", Immunomodulating Activity of Plant Polysaccharide Structures,
426. Elsevier Ltd. Amsterdam.
427. Zhang, B.-Z., Leung, W.K., Zou, Y.F., Mabusela, W., Johnson, Q., Michaelsen, T.E.,
428. Paulsen, B.S. 2014, Immunomodulating polysaccharides from *Lessertia frutescens*
429. leaves: Isolation, characterization and structure activity relationship. Journal of
430. Ethnopharmacology (2014), 152(2), 340-348.